A5025211248- BRCA gene mutations in cancer
- Cancer Immunotherapy and Biomarkers
- Hepatocellular Carcinoma Treatment and Prognosis
- Pancreatic and Hepatic Oncology Research
- Renal cell carcinoma treatment
- Immunotherapy and Immune Responses
- Ferroptosis and cancer prognosis
- Liver Disease Diagnosis and Treatment
- Hepatitis C virus research
- Cancer, Stress, Anesthesia, and Immune Response
- Colorectal Cancer Treatments and Studies
- Hepatitis B Virus Studies
- Family Support in Illness
- Childhood Cancer Survivors' Quality of Life
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Gastric Cancer Management and Outcomes
National Cancer Centre Singapore
2018-2025
Duke-NUS Medical School
2022-2024
Abstract Data about patient reported outcomes from cancer genetics services (CGS) are lacking but essential to guide service evaluation and improvements. We measured improvement in empowerment, following genetic counseling Singapore using a culturally‐adapted version of the Genetic Counseling Outcome Scale (GCOS‐24); sought identify factors associated with change empowerment. The GCOS‐24 was administered 155 patients CGS, at pre‐ post‐counseling or testing timepoints. Of which, 110 underwent...
Introduction Immune checkpoint blockade (ICB) is a systemic therapeutic option for advanced hepatocellular carcinoma (HCC). However, low patient response rates necessitate the development of robust predictive biomarkers that identify individuals who will benefit from ICB. A 4-gene inflammatory signature, comprising CD8 , PD-L1 LAG-3 and STAT1 was recently shown to be associated with better overall ICB in various cancer types. Here, we examined whether tissue protein expression CD8, PD-L1,...
The interaction of immune checkpoint inhibitors (ICI) and concomitant medications such as antibiotics, metformin, statins, beta-blockers, proton pump (PPIs), nonsteroidal anti-inflammatory drugs (NSAIDs), low-dose aspirin has been studied in other malignancies. Our study aims to investigate the relationship between these ICI efficacy patients with advanced hepatocellular carcinoma (aHCC).
1547 Background: Despite the demand for cancer genetic services, patient-derived benefits remain poorly captured due to a paucity of validated tools. The Genetic Counselling Outcome Scale (GCOS-24), genetics-specific Patient Reported Measure (PROM), has been adapted evaluate our local service (CGS). We aim psychometric properties GCOS-24 using Rasch analysis. Methods: 155 patients who attended CGS at National Cancer Centre Singapore (May 2016-2017) were recruited. questionnaire was...
<h3>Background</h3> Multiple clinical trials have shown an overall improved response rate in hepatocellular carcinoma (HCC) by combining radiotherapy (RT) with immunotherapy (IO), however, treatment rates remain low and unpredictable.<sup>1</sup> The suboptimal outcomes are largely due to the lack of knowledge underlying immunomodulation effect effective treatment-response biomarker. Previous studies using tissue-based assays like multiplexed immunofluorescence (mIF) demonstrated that...